MAPT and tauopathy: Treatment with KU-177, which binds specifically to Aha1, reduced the accumulation of insoluble P301L tau in cultured cells, suggesting that Aha1 may be a promising therapeutic target for tauopathies by directly reducing tau aggregation [111].